New cancer drug NRM-823 enters human trials for 9 tumor types
NCT ID NCT07182149
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This early-stage trial tests NRM-823, a drug designed to help the immune system fight cancer, in 150 people with advanced solid tumors like lung, breast, and ovarian cancer. The study gives NRM-823 alone or with another immunotherapy to see if it is safe and tolerable. The main goal is to check for side effects and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Normunity Investigational Site
RECRUITINGDenver, Colorado, 80220, United States
-
Normunity Investigational Site
RECRUITINGNew Haven, Connecticut, 06519, United States
-
Normunity Investigational Site
RECRUITINGMinneapolis, Minnesota, 55425, United States
-
Normunity Investigational Site
RECRUITINGMaumee, Ohio, 43537, United States
-
Normunity Investigational Site
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Normunity Investigational Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Normunity Investigational Site
RECRUITINGDallas, Texas, 75230, United States
-
Normunity Investigational Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Normunity Investigational Site
RECRUITINGFairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NRM-823 (a bispecific T-cell engager drug)
What this could lead to
If successful, this could point toward a new treatment option for several hard-to-treat cancers by helping the immune system attack tumors.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if NRM-823 will work. Side effects could be significant, and the drug may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.